Prihlásiť sa Zaregistrujte sa zadarmo

% krátkych akcií spoločnosti OncoSec Medical Inc

Aká je hodnota metriky % krátkych akcií spoločnosti OncoSec Medical Inc?

Hodnota metriky % krátkych akcií spoločnosti OncoSec Medical Inc je 68.36%

Aká je definícia metriky % krátkych akcií?



% krátkych akcií (Short % of float) je počet akcií predaných na krátko v porovnaní so všetkými akciami v obehu (float) vyjadrený v percentách.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

% krátkych akcií spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou OncoSec Medical Inc

Čomu sa venuje spoločnosť OncoSec Medical Inc?

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar

Firmy s metrikou % krátkych akcií podobnou spoločnosti OncoSec Medical Inc